Introduction
============

Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) responsible for recognizing conserved pathogen-associated molecular patterns (PAMPs). Engagement of TLRs initiates intracellular signalling pathways leading to the synthesis and secretion of various cytokines and chemokines by cells of the innate immune system. TLR-induced innate immune responses are also a prerequisite for the generation of most adaptive immune responses. TLRs therefore represent the first line of host defence against pathogens and play a pivotal role in both innate and adaptive immunity. In recent years, increasing evidence demonstrates that, under many pathological conditions, endogenous stimulators can activate TLR signalling to trigger a sterile inflammatory response. We review research progress on endogenous TLR ligands and their biological effects in non-infectious inflammation conditions such as tissue injury, tissue repair and regeneration, autoimmune disease and tumorigenesis.

TLR signalling
==============

Eleven human TLRs and 13 mouse TLRs have been identified. Each TLR recognizes distinct PAMPs derived from various microorganisms including bacteria, viruses, protozoa and fungi \[[@b1]\]. TLRs are generally divided into three groups: those that recognize lipids and lipopeptides (TLR1, 2, 4 and 6), proteins (TLR5 and mouse TLR11) and nucleic acids (TLR3, 7, 8 and 9) \[[@b2]\]. TLR1 forms heterodimers with TLR2 (TLR1/2) and recognizes triacyl lipopeptides \[[@b3]\]. TLR2 in concert with TLR1 or TLR6 recognizes a wide variety of PAMPs, including peptidoglycan, lipopeptides and lipoproteins of gram^+^ bacteria, mycoplasma lipopeptides and fungal zymosan \[[@b4]\]. Heterodimerization of TLRs extends the spectrum of ligands recognized. TLR4, together with its extracellular components such as MD-2 and CD14, recognizes lipopolysaccharide (LPS), a constituent of cell walls of gram^--^ bacteria \[[@b5]\]. In addition, studies in mice show that TLR4 recognizes not only bacterial motifs, but also viral motifs \[[@b6]\] and the plant product taxol \[[@b7]\]. TLR6 in association with TLR2 (TLR2/6) recognizes diacyl lipopeptides \[[@b8]\]. TLRs recognizing nucleic acids are localized in cytoplasmic compartments where they detect DNA and RNA derived from viruses and bacteria. TLR3 recognizes double-strand RNA \[[@b9]\], and TLR7 and TLR8 are responsive to the single-strand RNA \[[@b10]\] found during viral replication. TLR9 recognizes unmethylated deoxycytidyl-phosphate-deoxyguanosine (CpG) motifs commonly present in bacterial and viral genomes \[[@b11]\]. TLR5 recognizes bacterial flagellin \[[@b12]\] and TLR11 in mouse is responsive to a profilin-like molecule from the protozoan parasite Toxoplasma gondii \[[@b13]\]. Human TLR11 has been reported to be non-functional because of the presence of a stop codon in the gene \[[@b14]\]. TLR10 is able to homodimerize or heterodimerize with TLR1 and TLR2, but its ligand remains unknown \[[@b15]\].

Engagement of TLRs by PAMPs triggers intracellular signalling cascades through a set of toll/interleukin-1 receptor (TIR)-domain-containing adaptors, including myeloid differentiation primary response protein 88 (MyD88), TIR domain-containing adaptor protein (TIRAP/Mal), TIR domain-containing adaptor inducing interferon (IFN)-β (TRIF/TICAM1) and TRIF-related adaptor molecule (TRAM/TICAM2) ([Fig. 1](#fig01){ref-type="fig"}) \[[@b2]\]. Each TLR recruits a specific combination of adaptors to activate different transcription factors, giving rise to appropriate inflammatory responses. All TLRs, with exception of TLR3, share a common adaptor MyD88 to activate nuclear factor-κB (NF-κB) and activating protein-1 (AP-1) and induce the expression of various inflammatory cytokines through IL-1R-associated kinase (IRAK), tumour necrosis factor (TNF) receptor-associated factor-6 (TRAF6) and mitogen-activated protein (MAP) kinases (MyD88-dependent pathway) \[[@b2]\]. TIRAP mediates the activation of the MyD88-dependent pathway downstream of TLR2 and TLR4 \[[@b16], [@b17]\]. TRIF is recruited to TLR3 and TLR4 and mediates a MyD88-independent (TRIF-dependent) signalling pathway, leading to the activation of the late phase of NF-κB and IFN regulatory factor 3 (IRF3) and the subsequent production of type I IFN (IFN-α/β), IFN-inducible gene products and an immune regulatory response \[[@b18], [@b19]\]. TRAM selectively mediates the TRIF-dependent pathway downstream of TLR4, but not TLR3 \[[@b20]\].

![TLR4 signalling. TLR4 engagement initiates MyD88-dependent and independent signalling pathway and leads to production of inflammatory cytokines and type I IFN. AP-1, activating protein-1; CD14, cluster of differentiation 14; IKK, IκB kinase; IRAK, IL-1R-associated kinase; IRF, IFN regulatory factor; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MD-2, myeloid differentiation protein-2; MyD88, myeloid differentiation primary-response protein 88; TAK, TGF-β activated kinase; TBK, TANK binding kinase; TIRAP, Toll/interleukin-1 receptor domain-containing adaptor protein; TLR, toll-like receptor; TRAF, tumour necrosis factor receptor-associated factor; TRAM, TRIF-related adaptor molecule; TRIF, TIR-domain-containing adaptor inducing IFN-β; NF-κB, nuclear factor kappa B.](jcmm0014-2592-f1){#fig01}

Endogenous TLR ligands
======================

Recognition of microbial ligands fails to explain all functions of TLRs \[[@b21]\]. In addition to microbial PAMPs, an increasing number of endogenous stimulators are being reported as candidate ligands of TLRs (for review \[[@b22]--[@b25]\]). These endogenous molecules activate TLR signalling and induce sterile inflammatory responses in many pathological processes. Endogenous TLR ligands are a group of molecules derived from host tissues or cells, either components of cells or induced gene products in specific conditions. The majority are extracellular matrix components \[[@b22], [@b26]\] such as fibronectin \[[@b27]\], heparan sulphate \[[@b28]\], biglycan \[[@b29]\], fibrinogen \[[@b30]\], oligosaccharides of hyaluronan \[[@b31]\] and hyaluronan breakdown fragments \[[@b32]--[@b34]\]. Apart from previously identified protein ligands, for example high-mobility group box 1 (HMGB1) and heat shock proteins (HSP), it appears that more proteins such as tenascin-C, cardiac myosin and S100 proteins are implicated \[[@b35]--[@b38]\]. These so-called endogenous TLR ligands and their receptors are localized in different cellular compartments and cannot interact physiologically. In pathological conditions, endogenous ligands are either released passively from injured/inflamed tissues and dying cells or actively secreted by activated cells *via* a non-conventional lysosomal route \[[@b39]\]. Furthermore, it seems that even apoptotic cells, such as hypertrophic chondrocytes, may release some endogenous TLR ligands \[[@b40]\]. Endogenous TLR ligands can be categorized according to their properties ([Table 1](#tbl1){ref-type="table"}). Most are agonists of TLR4 and TLR2 ([Table 2](#tbl2){ref-type="table"}). Only a few bind to and stimulate other TLRs, but a single endogenous molecule, for example HMGB1, has the potential to interact with several TLRs \[[@b21], [@b41], [@b42]\].

###### 

Putative endogenous TLR ligands

  **Property of ligands**            **Ligands and references**
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Proteins and peptides              β-defensin 2 \[[@b47], [@b48]\], fibrinogen \[[@b30]\], fibronectin \[[@b27]\], HMGB1 \[[@b21], [@b49], [@b50]\], HSP (HSP22, HSP60, HSP70, HSP72, endoplasmin and α-crystallin A chain) \[[@b51]--[@b60]\], human cardiac myosin \[[@b38]\], resistin \[[@b61]\], S100 proteins \[[@b35], [@b36]\], surfactant protein A \[[@b62]\] and tenascin-C \[[@b37]\]
  Polysaccharides and proteoglycan   Biglycan \[[@b29]\], CD138 \[[@b23]\], heparan sulphate \[[@b28]\], oligosaccharides of hyaluronan \[[@b31]\] and hyaluronan breakdown fragments \[[@b32]--[@b34], [@b63]\]
  Nucleic acids                      DNA \[[@b64], [@b65]\], RNA \[[@b66], [@b67]\], mRNA \[[@b68], [@b69]\] and small interfering RNA (siRNA) \[[@b70]\]
  Phospholipids                      OxPAPC \[[@b71]\]
  Small organic molecules            Monosodium urate crystals \[[@b72], [@b73]\]

###### 

TLRs and their corresponding endogenous ligands

  TLRs   Ligands and references
  ------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  TLR2   Biglycan \[[@b29]\], endoplasmin \[[@b56]\], HMGB1 \[[@b74]\], HSP60 \[[@b52]\], HSP70 \[[@b53], [@b54]\], human cardiac myosin \[[@b38]\], hyaluronan \[[@b32], [@b63], [@b75]\] and monosodium urate crystals \[[@b72], [@b73]\]
  TLR3   mRNA \[[@b68], [@b69]\]
  TLR4   Biglycan \[[@b29]\], CD138 \[[@b23]\], α-crystallin A chain \[[@b57]\], β-defensin 2 \[[@b47], [@b48]\], endoplasmin \[[@b56]\], fibrinogen \[[@b30]\], fibronectin \[[@b27]\], heparan sulphate \[[@b28]\], HMGB1 \[[@b21], [@b41]\], HSP22 \[[@b57]\], HSP60 \[[@b51], [@b52], [@b60]\], HSP70 \[[@b53]--[@b55]\], HSP72 \[[@b58], [@b59]\], hyaluronan \[[@b32], [@b75], [@b76]\], monosodium urate crystals \[[@b72], [@b73]\], OxPAPC \[[@b71]\], resistin \[[@b61]\], S100 proteins \[[@b35], [@b36]\], surfactant protein A \[[@b62]\] and tenascin-C \[[@b37]\]
  TLR7   RNA \[[@b66], [@b67]\] and small interfering RNA (siRNA) \[[@b70]\]
  TLR8   Human cardiac myosin \[[@b38]\] and small interfering RNA (siRNA) \[[@b70]\]
  TLR9   DNA \[[@b64], [@b65]\] and HMGB1\[[@b42]\]

Endogenous TLR ligands are often referred to as alarmins and serve as early warning signals to innate and adaptive immune systems. Matzinger \[[@b43], [@b44]\] has suggested that the activation of the innate immune system is not only based on the recognition of PAMPs but also relies on the presence of danger signals or danger-associated molecular patterns (DAMPs) released by injured cells. As tissue damage and cell lysis are often associated with infections and lead to the release of host molecules, recognition of DAMPs enables the immune system to not only sense an ongoing infection and recruit more immune cells, but also to initiate the repair of damaged tissue \[[@b45]\]. The endogenous alarmins and exogenous PAMPs are subgroups of the larger category of danger signals termed damage-associated molecular patterns (DAMPs) \[[@b46]\].

Biological significance of signalling triggered by endogenous TLR ligands
=========================================================================

The inflammatory signals in some pathological situations, such as trauma and ischemia/reperfusion (I/R) injury, are activated even in the absence of infection. Evidence is accumulating that tissue damage is recognized at the cell level *via* receptor-mediated detection of endogenous molecules released by dead cells \[[@b46]\]. This is believed to be the major contribution of TLRs and inflammasome \[[@b77], [@b78]\]. Inflammasome is a large cytoplasmic molecular complex involved in the activation of inflammatory caspases resulting in the proteolytic activation of the pro-inflammatory cytokines IL-1β and IL-18 \[[@b78]\]. Cell disruption activates the inflammasome and initiates inflammatory responses. The inflammasome also senses extracellular danger signal ATP *via* purinoreceptor P2×7 \[[@b78]\]. Since an excellent review of the inflammasome has been published \[[@b78]\], it is not the focus of this review. TLR-mediated sterile inflammation, triggered by endogenous ligands, is involved in many pathological processes.

Ischemia and reperfusion injury
-------------------------------

Ischemia/reperfusion injury is implicated in a broad array of pathological conditions such as myocardial infarction; cerebral stroke; and hepatic, renal and intestinal ischemia as well as following cardiovascular and transplant surgery \[[@b77]\]. The hallmark of these pathologies is extreme inflammation. Massive tissue injury with a large number of cells undergoing necrosis lead to the release of DAMPs from dead and dying cells resulting in the activation of TLRs and sterile inflammation ([Fig. 2](#fig02){ref-type="fig"}) \[[@b79]\]. Most of the evidence for the existence of endogenous TLR ligands is based on the study of I/R injury, the majority of endogenous ligands are likely to be involved in the activation of TLRs in I/R injury \[[@b80]--[@b82]\], but a strong necrosis-induced inflammatory response may, at least in part, be mediated by HMGB1 \[[@b83]\].

![A proposed mechanism of inflammatory response in ischemia/reperfusion injury. Ischemia/reperfusion injury results in release of endogenous TLR ligands such as HMGB1, HSP and hyaluronan. Endogenous molecules bind to TLRs on DCs, macrophages and neutrophils that are recruited or infiltrated to injury sites and induce production of cytokines and chemokines and an inflammatory response.](jcmm0014-2592-f2){#fig02}

The injury promoting roles of TLR4 are manifested in almost all organs as demonstrated by the protection of TLR4-deficient mice after hepatic, renal, cardiac and cerebral I/R \[[@b83]--[@b87]\]. Deficiency of TLR2, TLR4 or MyD88 leads to an attenuated myocardial inflammation, a smaller infarction size, better preserved ventricular function, and reduced ventricular remodelling after ischemic injury \[[@b88]\]. Much evidence points to endogenous TLR ligands as mediators of I/R-induced inflammation. The endotoxin blockade using the LPS-neutralizing agent (recombinant bactericidal/permeability-increasing protein) fails to protect mouse livers from warm I/R injury, and LPS-independent, heat-sensitive protein molecules contained in liver perfusates activate macrophages to produce TNF-α through the TLR4 pathway, providing evidence that endogenous TLR4 ligands are critical in the pathogenesis of liver I/R injury \[[@b89]\]. HMGB1 expression is rapidly up-regulated in hepatic and renal I/R injury and blockade of HMGB1 by a neutralizing antibody dramatically reduces hepatic injury in wild-type but not TLR4-deficient mice \[[@b83], [@b84]\]. HMGB1/TLR4 signalling induces generation of reactive oxygen species in hemorrhagic shock/resuscitation-activated neutrophils \[[@b90]\]. Tissue injury-induced neutrophil recruitment is reduced in mice treated with HMGB1 antibody \[[@b91]\] or HMGB1^−/−^ cells in comparison to HMGB1^+/+^ cells \[[@b92]\]. Monocytes challenged with necrotic HMGB1^−/−^ cells produce less TNF-α compared to those challenged with necrotic HMGB1^+/+^ cells \[[@b91]\]. In addition, HMGB1 stimulation enhances TLR4 expression in hepatic dendritic cells (DCs) *in vitro* and increasing numbers of hepatic DCs promote HMGB1-mediated I/R injury \[[@b93]\]. In adaptive immune cells, TLR4 expression is significantly increased on CD4^+^ T cells and CD8^+^ T cells after burn injury, which may be a mechanism for enhanced T-cell response late following burn injury \[[@b94]\].

Donor TLR4 and HMGB1 also contribute to graft inflammation and sterile injury following cold preservation and transplantation and may be associated with alloimmune responses after transplantation \[[@b93], [@b95], [@b96]\]. After cold I/R, grafts exhibit translocation of HMGB1 out of the nucleus of cardiac myocytes \[[@b96]\]. Administration of an anti-HMGB1 neutralizing antibody reduces TLR4-mediated cold I/R-induced inflammatory responses, suggesting that targeting TLR4 signalling may have value in preventing or treating post-ischemic acute organ injury after transplantation \[[@b96], [@b97]\].

TLR4 and/or TLR2 are responsible for the hyaluronan signalling \[[@b63], [@b75]\] and hyaluronan-induced inflammatory response \[[@b32], [@b98]\]. It has been reported that hyaluronan and biglycan are up-regulated in the I/R kidney, but their functional contribution to injury has not been characterized \[[@b84]\]. Hyaluronan is released during acute allograft rejection \[[@b75]\] and is released in higher levels in bronchial lavage fluid of patients with evidence of chronic lung rejection compared with lung transplant recipients who are free of this effect \[[@b81]\], suggesting that hyaluronan may mediate TLR activation in the setting of allograft rejection. It should be mentioned here that hyaluronan receptors CD44 and MD-2 are also important co-signalling molecules in the specific interaction between hyaluronan and TLR4 during sterile injury \[[@b34]\].

TLR3 has been shown to be an endogenous sensor of tissue necrosis during acute inflammatory events \[[@b69]\], and RNA escaping from damaged tissue or contained within endocytosed cells may serve as an endogenous ligand for TLR3 \[[@b68]\]. In experimental polymicrobial septic peritonitis and ischemic gut injury model, TLR3-deficient mice are protected from the lethal effects of sustained inflammation by a transient increase of inflammatory chemokine/cytokine \[[@b69]\]. Macrophages from TLR3-deficient mice respond normally to other TLR ligands but do not respond to RNA from necrotic neutrophils \[[@b69]\]. Anti-TLR3 antibody reduces generation of inflammatory chemokines of macrophages evoked by products of necrotic neutrophils, attenuates the tissue injury associated with gut ischemia and significantly decreases sepsis-induced mortality \[[@b69]\].

Tissue repair and regeneration
------------------------------

In addition to the injury-promoting role established in I/R injury \[[@b83]--[@b88]\], TLRs are crucial in the response to other tissue injuries and subsequent tissue repair and regeneration \[[@b22], [@b99]--[@b101]\]. TLR2/TLR4- and MyD88-deficient mice display an increased degree of bleomycin-induced lung injury \[[@b32]\] and dextran sulphate sodium (DSS)-induced intestinal epithelial injury \[[@b102], [@b103]\]. TLR signalling is required for the liver regeneration after partial hepatectomy \[[@b104]\] and the regeneration of intestinal epithelia following DSS-induced injury \[[@b102], [@b105]\]. Experimental hepatic fibrogenesis is significantly decreased in TLR4-deficient mice \[[@b106], [@b107]\]. A markedly slower healing of skin wounds has been observed in MyD88-deficient mice compared with wild-type, further suggesting a key role for TLR signalling in wound healing \[[@b108]\]. Interestingly, the R753Q polymorphism of the TLR2 gene has recently been found to be associated with severe ulcerative colitis, as the functional deficiency of the TLR2 variant leads to impaired wound healing \[[@b109]\].

TLR signalling in wound healing appears to be mediated by two classes of ligands: bacterial PAMPs and endogenous ligands \[[@b110]\]. It is believed that PAMPs from the commensal intestinal microbiota activate TLR signal pathways in the intestine to prevent epithelial injury as gut-sterilized mice display a similar increase in intestinal injury and DSS-induced death as MyD88-deficient mice \[[@b103]\]. The growth-promoting TLR ligand for liver restoration after hepatectomy may also derive from intestinal microbiota \[[@b110]\]. It is likely that this effect is dose dependent with lower concentrations mediating regeneration and higher concentrations mediating growth-suppressive responses \[[@b110]\]. A strong reduction of fibrogenesis in gut-sterilized mice implies a role of bacterial ligands from the intestine in promoting liver fibrogenesis \[[@b107]\]. Moreover, LPS induces a dose-dependent inhibition of keratinocyte migration and neutralizing antibodies to TLR4 and TLR2 relieve the migration inhibition, providing a possible explanation for the lack of healing found in ulcers \[[@b111]\]. Thus, detection of microbial patterns *via* epithelial TLRs directly regulates tissue homeostasis during the steady state and following injury \[[@b103], [@b105], [@b106], [@b112]\].

In sterile conditions, TLRs are likely to be activated by endogenous ligands that are released from necrotic cells \[[@b41], [@b91]\] or extracellular matrix components generated as a result of tissue injury \[[@b113]\]. Endogenous HMGB1 seems to be the predominant activator of TLR4 in I/R injury with a large number of cells undergoing necrosis \[[@b83]\]. In addition, it has been demonstrated that hyaluronan-mediated TLR signalling regulates tissue injury and repair \[[@b32], [@b76]\]. Hyaluronan fragments isolated from serum of mice with acute bleomycin-induced lung injury stimulate macrophage chemokine production, but this induction effect is completely abolished in TLR2/TLR4 double-deficient cells \[[@b32]\]. TLR2^−/−^/TLR4^−/−^ mice are more susceptible than control mice to bleomycin-induced lung injury, and administration of hyaluronan-blocking peptide generates a phenotype that is notably similar to the TLR2-/TLR4- and MyD88-deficient state following acute lung injury, suggesting that the interaction of hyaluronan fragments with TLRs regulates lung injury and repair *in vivo*\[[@b32]\]. Hyaluronan accumulation is increased in injured skin tissue relative to normal skin and exogenous application of hyaluronan promotes wound repair, further supporting the potential involvement of hyaluronan in the wound-healing process \[[@b76]\]. It has also been observed that hyaluronan stimulates B cells, which infiltrate wounds to produce interleukin-6 and transforming growth factor-β through TLR4 \[[@b76]\].

Endogenous ligands and autoimmune diseases
------------------------------------------

Numerous reports have demonstrated that microbial PAMPs can trigger the onset of autoimmune diseases such as rheumatoid arthritis (RA) and experimental allergic encephalomyelitis (EAE), the animal model for multiple sclerosis \[[@b114], [@b115]\]. Whether endogenous TLR ligands contribute to the onset or perpetuation of these diseases is less clear. Data from mouse model studies indicate that endogenous TLR ligands may be involved in the pathogenesis of some autoimmune diseases (for review, see \[[@b24], [@b114], [@b116]\]).

Augmented TLR expression has been observed within the central nervous system (CNS) during EAE, even in the absence of apparent microbial involvement \[[@b117]\]. MyD88-deficient mice are EAE resistant and show no brain inflammation. This protection is due partly to TLR9 signalling \[[@b117]\]. These data indicate that both TLR9 and MyD88 are essential modulators of EAE and implicate an endogenous TLR9-dependent signal exerting an encephalitogenic effect \[[@b117]\]. As TLR9 is functionally expressed in microglia, it is likely that the ligand in the CNS is derived from cells that are damaged by the pathogenic effector T cells \[[@b118]\]. However, research results are inconsistent \[[@b119], [@b120]\]. It has been reported that TLR4- and TLR9-deficient mice exhibit more severe EAE symptoms than wild-type mice \[[@b119]\] and that stimulation of TLR3 with poly I:C induces IFN-β secretion and suppresses EAE \[[@b120]\].

Bacterial DNA and peptidoglycans have been detected in the joints of patients with RA and other arthritides, where they might enhance synovial inflammation \[[@b121]\]. However, recent evidence indicates that endogenous TLR ligand-mediated signalling plays an important role in RA. Several TLRs are expressed or even up-regulated in human synovial tissue from RA patients \[[@b122]--[@b124]\]. The inflammation resolves more quickly in TLR4-deficient experimental arthritic mice than in control mice \[[@b125]\] and blocking TLR4 in mice with collagen-induced arthritis leads to reduced disease severity \[[@b126]\]. Serum and synovial fluid from RA patients stimulate TLR4-expressing CHO cells to up-regulate CD25 \[[@b127]\] and RA synovial membrane culture supernatants are able to activate human macrophages *via* TLR signalling, suggesting the involvement of an endogenous ligand in the pathogenesis of RA \[[@b128]\]. Several putative endogenous TLR ligands have been associated with RA. HMGB1 is detectable in the synovial fluid of RA patients \[[@b129]\] and its expression is increased in synovial fibroblasts of RA patients compared to osteoarthritis patients, and this may stimulate the release of pro-inflammatory cytokines by fibroblasts \[[@b130]\]. RNA released from necrotic synovial fluid cells was recently shown to activate synovial fibroblasts *via* TLR3 \[[@b124]\]. Chromatin-IgG complexes activate B cells by dual engagement of antigen receptors and TLR9 to produce rheumatoid factor, a class of autoantibodies \[[@b64]\]. DNase II-deficient mice develop chronic polyarthritis resembling human RA due to excessive release of DNA following cell death, which may contribute to TLR9 activation \[[@b131]\]. Tenascin-C is an extracellular matrix glycoprotein specifically expressed in inflamed rheumatoid joints \[[@b37]\]. Tenascin-C-deficient mice show rapid resolution of acute joint inflammation and are protected from erosive arthritis \[[@b37]\]. Administration of exogenous tenascin-C promotes joint inflammation in vivo and induces cytokine synthesis in *in vitro* cultures in a TLR4-dependent manner, indicating that tenascin-C is an endogenous TLR activator essential for maintaining inflammation in arthritic joint disease \[[@b37]\].

It has been demonstrated that mammalian DNA and RNA, in the form of immune complexes, are potent self-antigens for TLR9 and TLR7, respectively, and induce IFN-α production by plasmacytoid pre-dendritic cells, which may promote systemic lupus erythematosus (SLE) \[[@b67], [@b132]\]. As TLR7 and TLR9 are located in cytoplasmic compartments, it is believed that these autoantigens gain access to them through a receptor-mediated delivery. One such access route is the B cell receptor (BCR)-mediated endocytosis, which is available not only for microorganisms but also for endogenous ligands that are liberated from damaged cells and recognized by an autoreactive BCR \[[@b114]\]. DNA and DNA-associated autoantigens activate autoreactive B cells *via* sequential engagement of the BCR and TLR9 \[[@b64], [@b65]\], whereas RNA and RNA-associated autoantigens react through BCR/TLR7 \[[@b66]\]. Autoimmune-prone mice, lacking the TLR adaptor protein MyD88, have markedly reduced autoantibody titres, further supporting the suggestion that TLRs play a key role in autoantibody responses in SLE \[[@b66]\].

Tumorigenesis and tumour progression
------------------------------------

The study of the association of TLR signalling with tumours focuses primarily on the following three aspects. It has been found that TLR signal-mediated chronic inflammation is involved in tumorigenesis and that the activation of TLR signalling induces an antitumour T-cell response \[[@b41]\]. In addition, evidence indicates that TLRs are also expressed in tumour cells and tissues, and TLR signalling contributes to tumour progression and chemoresistance \[[@b133]--[@b135]\]. Moreover, it has been reported recently that dying tumour cells release endogenous TLR ligands \[[@b41], [@b74]\] that are involved in solid tumour progression \[[@b136], [@b137]\] and probably in leukemic cell growth \[[@b23]\].

HMGB1 is a major putative tumour-related TLR ligand. It has been revealed that the ability of chemotherapeutic agents to kill tumours is decreased in TLR4- and MyD88-deficient mice \[[@b41]\]. This is mainly attributed to HMGB1, released by chemotherapy-induced cell death, which activates TLR4 expressed by DCs and induces antitumour T-cell immunity \[[@b41]\]. Breast cancer patients with a TLR4 loss-of-function allele relapse more quickly after radiotherapy and chemotherapy than those carrying the normal TLR4 allele \[[@b41]\]. Mice with a mutated TLR4 develop more skin tumours than wild-type mice treated with mutagenic agent, suggesting that TLR4-dependent antitumour responses are important for inhibiting tumorigenesis \[[@b138]\]. HMGB1 released from dying tumour cells also activates TLR2 expressed on tumour-infiltrating myeloid DCs and mediates an effective anti-glioblastoma multiforme immune response \[[@b74]\]. TLR2 signalling can be specifically activated by supernatants from the drug-treated tumour cells and is blocked by a specific HMGB1 inhibitor glycyrrhizin or anti-HMGB1 antibodies \[[@b74]\]. Moreover, HMGB1 inhibitor or antibodies abolish therapeutic efficacy in the mouse model, highlighting the critical role of HMGB1-mediated TLR2 signalling to elicit tumour regression \[[@b74]\]. HMGB1 is released from melanoma, small cell lung carcinoma and glioma cells treated with radiation or temozolomide, and therapeutic efficacy is consistent with an increase in the level of circulating HMGB1 in an intracranial melanoma model \[[@b74]\]. In addition, HMGB1 is released by osteoclasts \[[@b139]\] and can stimulate adjacent multiple myeloma cells \[[@b23]\].

The extracellular matrix proteoglycan versican in Lewis lung carcinoma has been identified as a macrophage activator that acts through TLR2 and its co-receptors TLR6 and CD14 and strongly enhances Lewis lung carcinoma metastatic growth *via* TLR2/TLR6-mediated TNF-α secretion \[[@b140]\]. TLR4 serves as a functional receptor for serum amyloid A 3 in pre-metastatic lungs. Serum amyloid A 3 is induced by S100A8 and S100A9, stimulates NF-κB signalling and facilitates metastasis \[[@b141]\]. Small fragments of hyaluronan in melanoma might promote tumour invasiveness by inducing matrix metalloprotease- and cytokine expression in a TLR4-dependent manner \[[@b142]\]. In addition, heparan sulphate proteoglycan CD138 expressed on multiple myeloma cells can bind to TLR4 and act as an autocrine survival factor. Soluble CD138 and heparanase levels correlate with poor prognoses \[[@b23]\].

Other inflammatory responses mediated by endogenous TLR ligands
---------------------------------------------------------------

Several endogenous ligands are involved in the inflammatory responses of the respiratory tract. HSP72 is released and biologically active in the bronchoalveolar lavage fluid and can regulate airway epithelial cell cytokine expression and activate neutrophils *via* TLR4 \[[@b58], [@b59]\]. The endogenous oxidized phospholipid oxidized 1-palmitoyl-2-arachidonoyl-phosphatidylcholine (OxPAPC) has been demonstrated recently to induce acute lung injury and cytokine production by lung macrophages through TLR4-TRIF signalling \[[@b71]\]. TLR3 expression is increased in airway epithelial cells from patients with acute respiratory distress syndrome \[[@b143]\]. TLR3-deficiency or administration of anti-TLR3 antibody to wild-type mice protects these animals from hyperoxia-induced lung injury and inflammation in the absence of a viral pathogen, suggesting an important role of TLR3 signalling and the possible involvement of endogenous TLR3 ligands \[[@b143]\]. In addition, even mechanical ventilation significantly increases endogenous TLR4 ligands in bronchoalveolar lavage fluid and induces a TLR4-dependent inflammatory response in healthy mice \[[@b144]\].

Endogenous TLR stimulators have the potential to induce cardiac and vascular inflammation. Human cardiac myosin acts as an endogenous ligand to directly stimulate TLR2 and TLR8 and activate monocytes to release pro-inflammatory cytokines, which can promote chronic inflammation in the myocardium \[[@b38]\]. Minimally oxidized low-density lipoprotein (mmLDL) stimulates intracellular reactive oxygen species generation in macrophages in a TLR4-dependent manner, suggesting that mmLDL can serve as an endogenous TLR4 ligand inducing proatherogenic activation of macrophages. This suggests a causative role in the development of atherosclerosis \[[@b145]\]. It has been reported that oxidized LDL and amyloid-b can trigger inflammatory signalling through a heterodimer of TLR4 and TLR6 \[[@b146]\]. In addition, Mrp8 and Mrp14, two members of the S100 family of calcium-modulated proteins, broadly regulate vascular inflammation and contribute to the biological response to vascular injury by promoting leucocyte recruitment \[[@b36]\]. They have been revealed to be endogenous activators of TLR4, promoting lethal, endotoxin-induced shock \[[@b35]\].

Uric acid, the end-product of the cellular catabolism of purines, is a danger-associated molecule involved in gout, an acute arthritis caused by deposits of monosodium urate monohydrate (MSU) crystals in joints. TLR2, TLR4 and MyD88 are required for MSU crystals-induced cytokine expression by macrophages and required for mouse air pouch inflammation as well a response to MSU crystal. This indicates that specific TLRs expressed in innate immune cells recognize naked MSU crystals and regulate the course of gouty arthritis \[[@b72]\]. TLR2 expression is up-regulated in osteoarthritic cartilage chondrocytes and blockage of TLR2 on chondrocytes suppresses MSU crystal-induced release of nitric oxide, an inflammation mediator \[[@b73]\]. Moreover, engagement of CD14, a TLR2 and TLR4 co-receptor, mediates the inflammatory potential of MSU crystals \[[@b147]\]. Apart from involvement in gouty arthritis, uric acid released from injured cells constitutes a major endogenous danger signal that activates the NACHT (NAIP, CIITA, HET-E and TP-1) domain, leucine-rich repeat and pyrin domain-containing protein (NALP)3 inflammasome and initiates sterile inflammation in other organs, for example in lung injury inflammation and fibrosis \[[@b148]\].

Sterile inflammation in the injured nervous system can also be triggered by endogenous TLR signals (for review \[[@b149]\]). HSPs including HSP60 and HSP70 are locally expressed by injured axons \[[@b150]\] and released by CNS cells undergoing necrotic or apoptotic cell death \[[@b60]\]. HSP60 can activate TLR4 at the surface of microglia and mediate neuro-inflammation through a MyD88-dependent pathway \[[@b60]\]. Necrotic neuronal cells induce inflammatory Schwann cell activation *via* TLR2 and TLR3, which may be involved in Wallerian degeneration upon peripheral nerve injury \[[@b151]\]. Furthermore, TLR signalling may play a critical role in orchestrating the innate immune response leading to efficient and rapid clearance of inhibitory myelin debris and nerve regeneration \[[@b152]\].

Conclusions
===========

Toll was first found to be a receptor involved in embryonic development of the fly \[[@b153]\]. TLRs, its mammalian homologues, were first discovered in 1997 \[[@b154]\] and were quickly demonstrated to be responsible for the recognition of microbial components \[[@b5]\]. In addition to binding to microbial PAMPs and involvement in host defence against pathogens, TLRs are involved in many sterile inflammation processes. The ability of TLRs to recognize endogenous mediators appears to be necessary for their ability to regulate sterile inflammation \[[@b110]\]. However, the biochemical evidence for the direct interaction of TLRs with endogenous stimulators is limited \[[@b35], [@b61]\]. Most evidence is provided from *in vitro* studies which have potential for contamination of bacterial TLR agonists, particularly those from commercial sources or recombinant products expressed in bacterial systems \[[@b25], [@b63]\]. For example, recombinant human HSP70 preparation has been reported to be contaminated by LPS \[[@b155]\]. Thus, *in vivo*= studies and biochemical evidence are essential for endogenous ligands to be widely accepted. *In vivo* studies suggest that matrix components biglycan and hyaluronan are endogenous TLR ligands \[[@b32], [@b63]\]. Although there is ongoing controversy concerning some putative endogenous ligands \[[@b110], [@b156], [@b157]\], accumulating evidence supports the suggestion that several endogenous TLR activators regulate some important non-infectious pathological events. Signalling mediated by endogenous ligands plays a pivotal role in sterile inflammation contributing to tissue injury and repair, autoimmune disease and tumorigenesis.

Despite rapid progress in understanding the broad roles of endogenous TLR ligands and their signalling, a number of questions remain unanswered. Initially, the specific contributions of endogenous TLR ligands to sterile inflammation need to be further evaluated, especially when the effects of microbial components cannot be eliminated. An interesting question is whether TLRs distinguish microbial ligands from endogenous ligands and respond differently. Many reported endogenous ligands ([Table 2](#tbl2){ref-type="table"}) have the potential to activate both TLR2 and TLR4. As far as we know, TLR2 and TLR4 recognize different microbial ligands. How do these receptors sense the same endogenous stimulators? Is it possible that they form a TLR2/4 heterodimer? As mentioned above, TLRs do not behave as singular molecular units, but form various heterodimers, which increases the versatility of the system. In addition to heterodimerization of TLR2 with TLR1 or TLR6 \[[@b3], [@b4], [@b8]\], a TLR4 and TLR6 heterodimer has recently been demonstrated to sense oxidized LDL and amyloid-β\[[@b146]\]. The scavenger receptor CD36, acting as a TLR4/TLR6 co-receptor, regulates TLR4/TLR6 complex formation and promotes sterile inflammation \[[@b146]\]. In addition, the endogenous stimulators for TLR2 or TLR4 vary greatly in their chemical properties. How can an individual TLR sense several agonists with different properties? It seems difficult to find a common moiety or structure among those molecules. It is more logical to postulate that different co-receptors or accessory molecules mediate interaction of an individual endogenous stimulator with a corresponding TLR. Then, the question is, which is the dominant endogenous activator for each TLR, if such exists? Moreover, in addition to interaction with TLRs, some endogenous molecules are able to stimulate other receptors, such as HMGB1 binding to the receptor for advanced glycation end products and hyaluronan acting on its receptor CD44. It is therefore necessary to estimate the respective contributions of individual receptors. There is no doubt that it is of great significance to identify the endogenous TLR ligands and elucidate their biological functions.
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